Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence.

A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int (2013) 1.02

Large genomic rearrangements of BRCA1 and BRCA2 among patients referred for genetic analysis in Galicia (NW Spain): delimitation and mechanism of three novel BRCA1 rearrangements. PLoS One (2014) 0.77

Genomic Disparities in Breast Cancer Among Latinas. Cancer Control (2016) 0.76

Hereditary cancer syndromes in Latino populations: genetic characterization and surveillance guidelines. Hered Cancer Clin Pract (2017) 0.75

Screening of the BRCA1 gene in Brazilian patients with breast and/or ovarian cancer via high-resolution melting reaction analysis. Fam Cancer (2016) 0.75

BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study. Fam Cancer (2015) 0.75

Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers. Fam Cancer (2017) 0.75

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (1994) 36.53

Identification of the breast cancer susceptibility gene BRCA2. Nature (1996) 17.14

Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res (2002) 16.02

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09

Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat (2000) 13.25

Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol (2002) 6.69

Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci U S A (1993) 5.47

A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet (1996) 4.38

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique (2004) 3.61

Population genetics of BRCA1 and BRCA2. Am J Hum Genet (1997) 3.28

Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet (1996) 2.97

Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst (2001) 2.74

The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet (1999) 2.03

Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet (1998) 1.61

Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat (2003) 1.54

The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat (2001) 1.36

Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res (2001) 1.14

The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat (2007) 1.10

Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis. PLoS One (2012) 1.02

Ethnic differences in cancer risk resulting from genetic variation. Cancer (1999) 0.99

Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. Int J Cancer (2002) 0.95

Age-dependent penetrance of different germline mutations in the BRCA1 gene. J Clin Pathol (2009) 0.91

Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling. Breast Cancer Res Treat (2007) 0.91

Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area: implications for genetic testing. Fam Cancer (2010) 0.90

Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain. Hum Mutat (2002) 0.87

Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation. Breast Cancer Res Treat (2003) 0.82

Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1. Breast Cancer Res Treat (2008) 0.82

High proportion of novel mutations of BRCA1 and BRCA2 in breast/ovarian cancer patients from Castilla-León (central Spain). J Hum Genet (2006) 0.80

Broad BRCA1 and BRCA2 mutational spectrum and high incidence of recurrent and novel mutations in the eastern Spain population. Breast Cancer Res Treat (2009) 0.78

[BRCA1 and BRCA2 mutations in families studied in the program of genetic counselling in cancer of the Valencian community (Spain)]. Med Clin (Barc) (2008) 0.78

Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel. Breast Cancer Res Treat (2012) 0.76

Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain. Breast Cancer Res Treat (2007) 0.76

Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management. Semin Diagn Pathol (2013) 1.80

Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2009) 0.97

MicroRNA signatures in hereditary breast cancer. Breast Cancer Res Treat (2013) 0.91

CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers. Breast Cancer Res Treat (2009) 0.89

[Programme of screening for colorrectal cancer in the Valencia community, Spain: results of the first round (2005-2008)]. Rev Esp Salud Publica (2011) 0.87

Advantages of the high resolution melting in the detection of BRCA1 or BRCA2 mutation carriers. Clin Biochem (2009) 0.85

Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma. Virchows Arch (2013) 0.85

Identification of a novel BRCA1 large genomic rearrangement in a Spanish breast/ovarian cancer family. Breast Cancer Res Treat (2007) 0.78

[BRCA1 and BRCA2 mutations in families studied in the program of genetic counselling in cancer of the Valencian community (Spain)]. Med Clin (Barc) (2008) 0.78

Broad BRCA1 and BRCA2 mutational spectrum and high incidence of recurrent and novel mutations in the eastern Spain population. Breast Cancer Res Treat (2009) 0.78

Low prevalence of BRCA1 and BRCA2 mutations in the sporadic breast cancer of Spanish population. Fam Cancer (2012) 0.77

Relationship of BRCA1 and BRCA2 mutations with cancer burden in the family and tumor incidence. Fam Cancer (2010) 0.77

Low penetrance alleles as risk modifiers in familial and sporadic breast cancer. Fam Cancer (2012) 0.77

[Molecular study of the BRCA1 and BRCA2 genes in 153 breast cancer families from Castilla and León (Spain): new nine unclassified variants identified]. Med Clin (Barc) (2002) 0.76

Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain. Breast Cancer Res Treat (2007) 0.76

[Women's satisfaction with waiting times for further investigation in breast cancer screening]. Gac Sanit (2011) 0.75